|
May 21
|
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
|
|
May 21
|
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
|
|
May 21
|
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
|
|
May 21
|
3 Promising Growth Stocks You Can Buy for Less Than $100
|
|
May 20
|
Top Research Reports for Visa, AstraZeneca & Shell
|
|
May 20
|
AstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks
|
|
May 20
|
AstraZeneca says Airsupra reduced severe asthma risk by 47%
|
|
May 20
|
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%
|
|
May 19
|
Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial
|
|
May 19
|
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
|
|
May 13
|
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
|
|
May 13
|
MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD
|
|
May 12
|
London stocks strike month-high after US-China tariff deal
|
|
May 12
|
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower
|
|
May 12
|
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
|
|
May 12
|
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
|
|
May 12
|
Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices
|
|
May 12
|
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
|
|
May 10
|
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer
|
|
May 9
|
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
|